Seeking Alpha

JPMorgan says there's a strong likelihood the FDA is going to approve Amarin's (AMRN) high...

JPMorgan says there's a strong likelihood the FDA is going to approve Amarin's (AMRN) high triglyceride drug AMR101 when it meets on Thursday. Based on the approval, the firm sees a fair price for the shares of around $22 by the end the year. Expect some volatility on the way however, the last time the stock hit those levels was clear back in 2007.
Comments (2)
  • I am long AMRN regardless what JPM says. All the share holders will be rewarded more then $22 my guess is $24-$26. Like to hear other thoughts please.
    23 Jul 2012, 08:40 PM Reply Like
  • The $22 PT does NOT include takeout or major partnership.
    24 Jul 2012, 08:52 AM Reply Like
DJIA (DIA) S&P 500 (SPY)